[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351355-105":59,"doc-detail-351355-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","declined-rtn3-stabilizes-dhcr7-to-induce-cholesterol-dependent-tumor-progression-and-mek-inhibitors-insensitivity-in-thyroid-cancer","Declined RTN3 stabilizes DHCR7 to induce cholesterol-dependent tumor progression and MEK inhibitors insensitivity in thyroid cancer","","Thyroid cancer progression and resistance to MEK inhibitors remain unresolved clinical problems. Endoplasmic reticulum (ER) proteins regulate tumor biosynthesis and survival, yet the function of Reticulon 3 (RTN3) in thyroid cancer is unclear. Cholesterol is implicated in proliferation and drug resistance, motivating investigation into how RTN3 controls cholesterol levels and affects MEK inhibitor sensitivity. RTN3 is low in tumors, associates with poor outcomes, binds DHCR7, and promotes ubiquitination, increasing EGFR/ERK signaling and progression, reversible by simvastatin.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/declined-rtn3-stabilizes-dhcr7-to-induce-cholesterol-dependent-tumor-progression-and-mek-inhibitors-insensitivity-in-thyroid-cancer/351355/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/declined-rtn3-stabilizes-dhcr7-to-induce-cholesterol-dependent-tumor-progression-and-mek-inhibitors-insensitivity-in-thyroid-cancer/351355.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main question this study addresses about RTN3 in thyroid cancer?","Question",{"text":112,"@type":113},"How RTN3 regulates cholesterol concentration and whether this regulation influences tumor progression and sensitivity to MEK inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What relationship did the study find between RTN3 expression and MEK inhibitor sensitivity?",{"text":117,"@type":113},"RTN3 is low-expressed in thyroid cancer, correlating with poor prognosis and insensitivity to MEK inhibitors.",{"name":119,"@type":110,"acceptedAnswer":120},"How does RTN3 mechanistically affect cholesterol signaling and tumor progression?",{"text":121,"@type":113},"RTN3 binds the cholesterol synthesis enzyme DHCR7 and promotes its ubiquitination; downregulation stabilizes DHCR7, elevates cholesterol, activates the EGFR/ERK pathway, and drives progression, which can be rescued by simvastatin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351355,1790171055,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nDeclined RTN3 stabilizes DHCR7 to induce cholesteroldependent tumor progression and MEK inhibitors insensitivity in thyroid cancer  \nAnwen Ren 1,2,6, Nan Feng3,4,6, Tinglin Yang 1,6, Zimei Tang 1, Huan Liu1, Yi Li 1, Qingyi Hu 1, Zihan Xi1, Jiaqing Zhu5, Jun Zhou1, Jie Ming1, Nan Liu2, Tao Huang 1 ✉ and Ming Xu 1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Mechanism underlying thyroid cancer progression and treatment resistance remains an unsolved problem in clinical practice. Endoplasmic reticulum (ER) proteins modulate cell biosynthesis and mediate tumor progression, among which Reticulon 3 (RTN3) is veriﬁed to play important roles in cancers. However, its effect in thyroid cancer has not been clariﬁed. Meanwhile, cholesterol is found to contribute to proliferation and drug resistance in many tumors. As ER is the primary site of cholesterol synthesis, we aimed to study how RTN3 regulates cholesterol concentration and inﬂuences tumor progression and sensitivity to MEK inhibitors in thyroid cancer. This study found that RTN3 is low-expressed in thyroid cancer, and is related to poor prognosis and insensitivity to MEK inhibitors. It binds to a cholesterol synthesis enzyme DHCR7 and promotes its ubiquitination. Downregulation of RTN3 lead to stabilization of DHCR7 and elevate cholesterol concentration, activating EGFR/ERK pathway and contributes to progression of thyroid cancer, which can be rescued by HMG-CoA reductase inhibitor Simvastatin. We identiﬁed RTN3 as a tumor suppressor and abiomarker of sensitivity to MEK inhibitors and veriﬁed the role of cholesterol in drug resistance. The combination of statins provides |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| a novel therapeutic method in patients resistant to MEK inhibitors. |  |  |\n|  | Cell Death and Disease (2026)17:306; [https://doi.org/10.1038/s41419-026-08538-y](https://doi.org/10.1038/s41419-026-08538-y) |  |\n|  |  |  |\n\nINTRODUCTION  \nThyroid cancer is the most prevalent malignancy in endocrine system and has the 7th highest incidence of malignant tumors globally [1] . Following standard treatment, including surgery, thyroid-stimulating hormone suppression therapy, radioactive iodine therapy and target therapy (like BRAF and MEK inhibitors), the 10-year overall survival rate of patients can exceed 90%[2, 3] . However, approximately 5–15% of cases develop treatment resistance, manifesting as adverse clinical outcomes such as local recurrence, radioactive iodine refractoriness, distant metastasis, resistance to target drugs, and dedifferentiation, which signiﬁcantly impact patient prognosis [4] . Current research urgently needs to delve deeper into the molecular mechanisms underlying the pathogenesis and progression of thyroid cancer. By identifying key signaling pathways and biomarkers, novel therapeutic targets can be discovered to improve the progression-free survival of patients with refractory disease.  \nEndoplasmic reticulum (ER) proteins critically contribute to tumorigenesis by modulating cancer cell proliferation, apoptosis resistance, and microenvironment remodeling [5, 6] . Besides, many of them were demonstrated to be related to cancer drug  \nresistance [7, 8] . Reticulon 3 (RTN3) localizes to the luminal ER membrane via its C-terminal reticulon homology domain. It not only maintains ER homeostasis by facilitating tubular network formation, modulating autophagy, and regulating Ca²⁺ ﬂux, but has also been implicated in oncogenesis [9] . However, the roles of RTN3 in thyroid carcinogenesis and drug sensitivity remain unrevealed, and its molecular mechanisms for modulating malignant phenotypes are poorly understood.  \nThe role of metabolic reprogramming in tumorigenesis has gained increasing recognition in recent years [10] . Among all metabolites related to lipid synthesis, cholesterol plays a crucial role in tumor pr","cbCaihxhu1iFozfi","https://ap.wps.com/l/cbCaihxhu1iFozfi","pdf",7628814,14,"English","# Introduction\n## Thyroid cancer treatment resistance and unmet need\n## ER proteins and RTN3 in tumor biology\n## Cholesterol metabolism as a driver of progression and drug resistance","[{\"question\":\"What is the main question this study addresses about RTN3 in thyroid cancer?\",\"answer\":\"How RTN3 regulates cholesterol concentration and whether this regulation influences tumor progression and sensitivity to MEK inhibitors.\"},{\"question\":\"What relationship did the study find between RTN3 expression and MEK inhibitor sensitivity?\",\"answer\":\"RTN3 is low-expressed in thyroid cancer, correlating with poor prognosis and insensitivity to MEK inhibitors.\"},{\"question\":\"How does RTN3 mechanistically affect cholesterol signaling and tumor progression?\",\"answer\":\"RTN3 binds the cholesterol synthesis enzyme DHCR7 and promotes its ubiquitination; downregulation stabilizes DHCR7, elevates cholesterol, activates the EGFR/ERK pathway, and drives progression, which can be rescued by simvastatin.\"}]","Declined RTN3 stabilizes DHCR7 to induce cholesterol-dependent tumor progression and MEK inhibitors insensitivity in thyroid cancer | PDF",1790093696,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53ec1be93d859959575a1755a6499b93.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd370679dc5824a441c187fafd853676.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dadd4f683a56b59ee2f42cf356c82be.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e79ca0bb09a9c9995a290082bb6bf3a.webp",980,1301]